Cargando…
1593. Switch to DOVATO in Patients Suppressed on Biktarvy (The SOUND Study), week 48 interim analysis
BACKGROUND: Dolutegravir/lamivudine(DTG/3TC) is a complete regimen, approved by the FDA for the treatment of HIV-1 infection in treatment-naïve or virologically suppressed patients with no prior virologic failure or resistance to DTG/3TC. The SOUND study evaluated virologically suppressed (< 50 c...
Autores principales: | Slim, Jihad, Fallon, James, Abouzeid, Wassim, Fadoju-Oloyede, Helen, Shafiq, Amtus, Muhanna, Ala |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678138/ http://dx.doi.org/10.1093/ofid/ofad500.1428 |
Ejemplares similares
-
2489. Adverse Events with Biktarvy: Post-Marketing Study
por: Hayes, Edwin, et al.
Publicado: (2019) -
Effect of Food on the Pediatric Dispersible Tablet Formulations of TRIUMEQ and DOVATO in Healthy Adult Participants
por: Chandasana, Hardik, et al.
Publicado: (2023) -
1593 Predictors of Mortality for HIV-associated Cryptococcal Meningitis
por: Nimitvilai, Sireethorn, et al.
Publicado: (2014) -
When Influenza, Bacterial Pneumonia, and COVID-19 Co-exist
por: Owolabi, Modupeoluwa, et al.
Publicado: (2022) -
Vida del soldado español Miguel Castro, 1593-1611 : escrita por el mismo.
por: Castro, Miguel de, b.1593-
Publicado: (1949)